BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21678742)

  • 1. Assessing menopausal status in women aged 40 - 49 using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraception.
    Beksinska ME; Smit JA; Kleinschmidt I; Farley TM
    S Afr Med J; 2011 Feb; 101(2):131-5. PubMed ID: 21678742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception.
    Beksinska ME; Smit JA; Kleinschmidt I; Farley TM; Mbatha F
    Contraception; 2005 Mar; 71(3):170-5. PubMed ID: 15722065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of raised FSH levels among older women using depomedroxyprogesterone acetate and norethisterone enanthate.
    Beksinska ME; Smit JA; Kleinschmidt I; Rees HV; Farley TM; Guidozzi F
    Contraception; 2003 Nov; 68(5):339-43. PubMed ID: 14636937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate.
    Beksinska ME; Kleinschmidt I; Smit JA; Farley TM
    Contraception; 2009 May; 79(5):345-9. PubMed ID: 19341845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, nonusers and discontinuers of hormonal contraception.
    Beksinska ME; Smit JA; Kleinschmidt I; Milford C; Farley TM
    Contraception; 2010 Jan; 81(1):30-4. PubMed ID: 20004270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density in adolescents using norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives for contraception.
    Beksinska ME; Kleinschmidt I; Smit JA; Farley TM
    Contraception; 2007 Jun; 75(6):438-43. PubMed ID: 17519149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial.
    Singata-Madliki M; Smit J; Beksinska M; Balakrishna Y; Avenant C; Beesham I; Seocharan I; Batting J; Hapgood JP; Hofmeyr GJ
    PLoS One; 2024; 19(3):e0295764. PubMed ID: 38530848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mineral density in midlife long-term users of hormonal contraception in South Africa: relationship with obesity and menopausal status.
    Beksinska ME; Kleinschmidt I; Smit JA
    Womens Midlife Health; 2018; 4():6. PubMed ID: 30766716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility.
    Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile.
    Fahmy K; Abdel-Razik M; Shaaraway M; al-Kholy G; Saad S; Wagdi A; al-Azzony M
    Contraception; 1991 Oct; 44(4):419-30. PubMed ID: 1836754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depot medroxyprogesterone acetate and norethisterone enanthate differentially impact T-cell responses and expression of immunosuppressive markers.
    Matubu A; Hillier SL; Meyn LA; Stoner KA; Mhlanga F; Mbizvo M; Maramba A; Chirenje ZM; Achilles SL
    Am J Reprod Immunol; 2020 Mar; 83(3):e13210. PubMed ID: 31729087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final report.
    Contraception; 1983 Jul; 28(1):1-20. PubMed ID: 6226488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting hormonal contraceptives for women.
    Garza-Flores J; Hall PE; Perez-Palacios G
    J Steroid Biochem Mol Biol; 1991; 40(4-6):697-704. PubMed ID: 1958567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women.
    Lizarelli PM; Martins WP; Vieira CS; Soares GM; Franceschini SA; Ferriani RA; Patta MC
    Contraception; 2009 Jan; 79(1):35-40. PubMed ID: 19041439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic effects of once-a-month combined injectable contraceptives.
    Sang GW
    Contraception; 1994 Apr; 49(4):361-85. PubMed ID: 8013220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
    Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
    Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.
    Morrison CS; Chen PL; Kwok C; Baeten JM; Brown J; Crook AM; Van Damme L; Delany-Moretlwe S; Francis SC; Friedland BA; Hayes RJ; Heffron R; Kapiga S; Karim QA; Karpoff S; Kaul R; McClelland RS; McCormack S; McGrath N; Myer L; Rees H; van der Straten A; Watson-Jones D; van de Wijgert JH; Stalter R; Low N
    PLoS Med; 2015 Jan; 12(1):e1001778. PubMed ID: 25612136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
    Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mineral density in young women aged 19-24 after 4-5 years of exclusive and mixed use of hormonal contraception.
    Beksinska ME; Kleinschmidt I; Smit JA; Farley TM; Rees HV
    Contraception; 2009 Aug; 80(2):128-32. PubMed ID: 19631787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of different approaches to management of menstrual disturbances in women using injectable contraceptives.
    Fraser IS
    Contraception; 1983 Oct; 28(4):385-97. PubMed ID: 6230212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.